Literature DB >> 9426700

Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells.

G Corona1, F Giannini, M Fabris, G Toffoli, M Boiocchi.   

Abstract

Folate receptor-alpha (FR-alpha) is generally over-expressed in non-mucinous human ovarian carcinomas. The meaning of FR-alpha over-expression and its role in the 5-methyltetrahydrofolic acid (N5-CH3-H4PteGlu) transport in such tumors is not clear, especially compared with the reduced folate carrier (RFC), the other known folate transporter. In this study, we analyzed molecular FR-alpha and RFC expression in 16 ovarian carcinoma tissues and in 5 ovarian carcinoma cell lines using competitive PCR. Co-expression of the 2 transporters was found both in vivo and in vitro. FR-alpha mRNA expression in the cell lines was in good agreement with the corresponding protein expression evaluated by cellular folic acid binding and immunofluorescence analysis, using a specific monoclonal antibody (MAb) (MOv18). Moreover, RFC mRNA expression levels were consistent with the selective cellular binding of N-hydroxysuccinimide of [3H]-methotrexate (NHS-MTX). The 5 ovarian carcinoma cell lines (IGROV-1, SW-626, SKOV-3, OVCAR-3 and OAW-42), grown at physiological N5-CH3-H4PteGlu concentrations (20 nM) and expressing FR-alpha and RFC levels superimposable to those observed in vivo, were used as in vitro cellular model to evaluate the different contribution of FR-alpha and RFC to the transport of N5-CH3-H4PteGlu. The cytoplasmic N5-CH3-[3H]H4PteGlu accumulation observed in each cell line was approximately linear over 4 hr of incubation, but there was no correlation between the rate of folate internalization and FR-alpha and RFC expression levels. Furthermore, the selective inhibition of FR-alpha and RFC functionality allowed us to distinguish their differential role on the overall N5-CH3-[3H]H4PteGlu intracellular delivery. Treatment with the N-hydroxysuccinimide of folic acid, which blocks FR-alpha activity, showed only a partial inhibition (about 20%) of folate internalization in all the cell lines. In contrast, the inhibition of RFC by NHS-MTX, under conditions that did not affect FR-alpha functionality, generally reduced folate accumulation by more than 70%. Only one cell line (IGROV-1) showed a comparable contribution of the 2 transport systems. Our findings suggest that in ovarian carcinomas, in spite of its over-expression, FR-alpha generally plays a minor role in N5-CH3-H4PteGlu transport compared with RFC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9426700     DOI: 10.1002/(sici)1097-0215(19980105)75:1<125::aid-ijc19>3.0.co;2-f

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Synthesis of folate-functionalized RAFT polymers for targeted siRNA delivery.

Authors:  Danielle S W Benoit; Selvi Srinivasan; Andrew D Shubin; Patrick S Stayton
Journal:  Biomacromolecules       Date:  2011-06-10       Impact factor: 6.988

2.  Bacterial Folates Provide an Exogenous Signal for C. elegans Germline Stem Cell Proliferation.

Authors:  Snehal N Chaudhari; Madhumati Mukherjee; Alexandra S Vagasi; Gaofeng Bi; Mohammad M Rahman; Christine Q Nguyen; Ligi Paul; Jacob Selhub; Edward T Kipreos
Journal:  Dev Cell       Date:  2016-07-11       Impact factor: 12.270

3.  Revisiting the value of competition assays in folate receptor-mediated drug delivery.

Authors:  Steven K Jones; Anwesha Sarkar; Daniel P Feldmann; Peter Hoffmann; Olivia M Merkel
Journal:  Biomaterials       Date:  2017-05-22       Impact factor: 12.479

4.  A low molecular weight folate receptor targeted contrast agent for magnetic resonance tumor imaging.

Authors:  Tammy L Kalber; Nazila Kamaly; Po-Wah So; John A Pugh; Josephine Bunch; Cameron W McLeod; Michael R Jorgensen; Andrew D Miller; Jimmy D Bell
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

5.  Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia.

Authors:  Serkan Senol; Ayse Bahar Ceyran; Abdullah Aydin; Ebru Zemheri; Seyma Ozkanli; Duygu Kösemetin; Ibrahim Sehitoglu; Ibrahim Akalin
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  Emerging roles for folate receptor FOLR1 in signaling and cancer.

Authors:  Fathima Zahra Nawaz; Edward T Kipreos
Journal:  Trends Endocrinol Metab       Date:  2022-01-31       Impact factor: 12.015

7.  Folate-targeted nanoparticles based on albumin and albumin/alginate mixtures as controlled release systems of tamoxifen: synthesis and in vitro characterization.

Authors:  A Martínez; R Olmo; I Iglesias; J M Teijón; M D Blanco
Journal:  Pharm Res       Date:  2013-08-07       Impact factor: 4.200

8.  Relationship between dietary and supplemental intake of folate, methionine, vitamin B6 and folate receptor alpha expression in ovarian tumors.

Authors:  Joanne Kotsopoulos; Jonathan L Hecht; Jonathan D Marotti; Linda E Kelemen; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

9.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Authors:  David S Miller; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

10.  Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts.

Authors:  S D Konda; M Aref; S Wang; M Brechbiel; E C Wiener
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.